Release Date: 14/03/13 09:43 Summary: Letter to Shareholders - Non Renounceable Rights Issue Price Sensitive: No Download Document 154KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%